CC-486 Treatment of Acute Myeloid Leukemia: FDA Grants Priority Review
Time of Update: 2020-06-24
After about 3.5 years of median follow-up, the total survival (OS) in the CC-486 treatment group was 24.7 months and the placebo group OS was 14.8 months.
FDA approves for launch of Therapeutics MD's BIJUVA ™ capsule (1 mg/100 mg)
Time of Update: 2020-06-11
in line with FDA guidelines, the common primary therapeutic endpoint in this supplementary trial is a change in the value and severity of hot flashes in the 4th and 12th weeks in comparison to placebo.
Baxter Squibb CC-486 Maintenance Therapy Treats AML Patients In Phase 3 Key Trials Get Positive Results
Time of Update: 2020-06-07
In addition, the health ( associated quality of life (HRQoL) scores of CC-486 patients during treatment were maintained at baseline, reaching a critical secondary endpoint of the trial.
Configure CSF on CentOS 5 and 6 to prevent small-scale DDoS and CC attacks
Time of Update: 2020-04-03
Portload is a comma separated list: portload = "22; TCP; 5; 300,80; TCP; 20; 5" means: Third, connlimit connection protection this function can be used to limit the number of concurrent active connections from one IP address for each port.
Bayer company announced that it will carry out phase III clinical trial of new arbacicept 8 mg preparation
Time of Update: 2020-02-10
Bayer and regeneron pharmaceuticals, Inc
today announced that they will carry out two phase III studies, photon and pulsar, to assess the prolongation of the interval
First domestic PD-1 price announced, only 30 yuan / mg
Time of Update: 2019-01-08
On December 17, 2018, tuoyi, the first anti-PD-1 monoclonal antibody independently developed in China, was approved by the State Drug Administration for listing.